Gabriel Bohl

Gabriel Bohl is a senior regulatory affairs professional with expertise in regulatory strategy and clinical development for innovative biological medicinal products. Currently serving as the Director of Regulatory Affairs at ICON plc, they focus on CMC for Advanced Therapy Medicinal Products (ATMP) and biosimilars. Gabriel has held various positions in regulatory roles, including Scientific Officer at the European Pharmacopoeia and Eastern Europe Registration Manager at Synthelabo-Pharma. Their broad experience spans assessing drug master files, managing registration programs, and leading regulatory discussions, particularly in the realm of gene therapies and GMO products. Gabriel holds a Doctor of Pharmacy degree from Université Louis Pasteur (Strasbourg I).